A dose-response study in mice of a tetravalent vaccine candidate composed of domain III-capsid proteins from dengue viruses

Archives of Virology

Volumn 162, Issue 8, 2017, Pages 2247-2256

  Valdés, Iris ^a   Marcos, Ernesto ^a   Suzarte, Edith ^a   Pérez, Yusleidi ^a   Brown, Enma ^a   Lazo, Laura ^a   Cobas, Karem ^a   Yaugel, Melyssa ^a   Rodríguez, Yadira ^a   Gil, Lázaro ^a   Guillén, Gerardo ^a   Hermida, Lisset ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; DENGUE VACCINE; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; SUBUNIT VACCINE; VIRUS ANTIBODY;

ANIMAL; BAGG ALBINO MOUSE; BLOOD; BRAIN; CELLULAR IMMUNITY; CHLOROCEBUS AETHIOPS; DENGUE; DENGUE VIRUS; DISEASE MODEL; DOSE RESPONSE; FEMALE; GENETICS; HUMORAL IMMUNITY; IMMUNOLOGY; MOUSE; VERO CELL LINE; VIREMIA; VIROLOGY;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BRAIN; CAPSID PROTEINS; CERCOPITHECUS AETHIOPS; DENGUE; DENGUE VACCINES; DENGUE VIRUS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; MICE; MICE, INBRED BALB C; RECOMBINANT PROTEINS; VACCINES, SUBUNIT; VERO CELLS; VIREMIA;

EID: 85017115558     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00705-017-3360-y     Document Type: Article

References (44)

1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GR, Simmons CP, Scott TW, Farrar JJ, Hay SI (2013) The global distribution and burden of dengue. Nature 496:504–507
2. Halstead S (2008) Dengue, 1st edn. Imperial College Press, London
3. Gubler DJ (2002) Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol 10:100–103
4. Halstead SB (2007) Dengue. Lancet 370:1644–1652
5. Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, Luong CQ, Rusmil K, Wirawan DN, Nallusamy R, Pitisuttithum P, Thisyakorn U, Yoon IK, van der Vliet D, Langevin E, Laot T, Hutagalung Y, Frago C, Boaz M, Wartel TA, Tornieporth NG, Saville M, Bouckenooghe A (2014) Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 384:1358–1365
6. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel TA, Moureau A, Saville M, Bouckenooghe A, Viviani S, Tornieporth NG, Lang J (2012) Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 380:1559–1567
7. Villar LA, Rivera-Medina DM, Arredondo-Garcia JL, Boaz M, Starr-Spires L, Thakur M, Zambrano B, Miranda MC, Rivas E, Dayan GH (2013) Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9–16 year olds: a randomized, controlled, phase II trial in Latin America. Pediatr Infect Dis J 32:1102–1109
8. Villar L, Dayan GH, Arredondo-Garcia JL, Rivera DM, Cunha R, Deseda C, Reynales H, Costa MS, Morales-Ramirez JO, Carrasquilla G, Rey LC, Dietze R, Luz K, Rivas E, Miranda Montoya MC, Cortes SM, Zambrano B, Langevin E, Boaz M, Tornieporth N, Saville M, Noriega F (2015) Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 372:113–123
9. Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, Muhammad Ismail HI, Reynales H, Limkittikul K, Rivera-Medina DM, Tran HN, Bouckenooghe A, Chansinghakul D, Cortes M, Fanouillere K, Forrat R, Frago C, Gailhardou S, Jackson N, Noriega F, Plennevaux E, Wartel TA, Zambrano B, Saville M (2015) Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 373:1195–1206
10. Coudeville L, Baurin N, Vergu E (2015) Estimation of parameters related to vaccine efficacy and dengue transmission from two large phase III studies. Vaccine 34:6417–6425
11. Durbin AP, Kirkpatrick BD, Pierce KK, Carmolli MP, Tibery CM, Grier PL, Hynes N, Opert K, Jarvis AP, Sabundayo BP, McElvany BD, Sendra EA, Larsson CJ, Jo M, Lovchik JM, Luke CJ, Walsh MC, Fraser EA, Subbarao K, Whitehead SS (2016) A 12-month-interval dosing study in adults indicates that a single dose of the national institute of allergy and infectious diseases tetravalent dengue vaccine induces a robust neutralizing antibody response. J Infect Dis 214:832–835
12. WHO (2016) http://www.who.int/vaccine_safety/committee/reports/Jul_2016/en/. Dengue vaccine update (accessed 25.11.16)
13. Aguiar M, Stollenwerk N, Halstead SB (2016) The risks behind Dengvaxia recommendation. Lancet Infect Dis 16:882–883
14. Valdes I, Bernardo L, Gil L, Pavon A, Lazo L, Lopez C, Romero Y, Menendez I, Falcon V, Betancourt L, Martin J, Chinea G, Silva R, Guzman MG, Guillen G, Hermida L (2009) A novel fusion protein domain III-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice. Virology 394:249–258
15. Marcos E, Gil L, Lazo L, Izquierdo A, Brown E, Suzarte E, Valdes I, Garcia A, Mendez L, Guzman MG, Guillen G, Hermida L (2013) Purified and highly aggregated chimeric protein DIIIC-2 induces a functional immune response in mice against dengue 2 virus. Arch Virol 158:225–230
16. Gil L, Marcos E, Izquierdo A, Lazo L, Valdes I, Ambala P, Ochola L, Hitler R, Suzarte E, Alvarez M, Kimiti P, Ndung’u J, Kariuki T, Guzman MG, Guillen G, Hermida L (2014) The protein DIIIC-2, aggregated with a specific oligodeoxynucleotide and adjuvanted in alum, protects mice and monkeys against DENV-2. Immunol Cell Biol 93:57–66
17. Suzarte E, Gil L, Valdes I, Marcos E, Lazo L, Izquierdo A, Garcia A, Lopez L, Alvarez M, Perez Y, Castro J, Romero Y, Guzman MG, Guillen G, Hermida L (2015) A novel tetravalent formulation combining the four aggregated domain III-capsid proteins from dengue viruses induces a functional immune response in mice and monkeys. Int Immunol 27:367–379
18. Marcos E, Gil L, Izquierdo A, Lazo L, Suzarte E, Valdes I, Garcia A, Perez Y, Romero Y, Brown E, Guzman G, Guillen G, Hermida L (2015) A dose-response study in mice of the vaccine preparation containing the diiic-2 protein aggregated with the oligodeoxinucleotide 39m. Bionatura 1:4–19
19. Clarke DH, Casals J (1958) Techniques for hemagglutination and hemagglutination-inhibition with arthropod-borne viruses. Am J Trop Med Hyg 7:561–573
20. Halstead SB, Marchette NJ (2003) Biologic properties of dengue viruses following serial passage in primary dog kidney cells: studies at the University of Hawaii. Am J Trop Med Hyg 69:5–11
21. Suzarte E, Marcos E, Gil L, Valdes I, Lazo L, Ramos Y, Perez Y, Falcon V, Romero Y, Guzman MG, Gonzalez S, Kouri J, Guillen G, Hermida L (2014) Generation and characterization of potential dengue vaccine candidates based on domain III of the envelope protein and the capsid protein of the four serotypes of dengue virus. Arch Virol 159:1629–1640
22. Morens DM, Halstead SB, Repik PM, Putvatana R, Raybourne N (1985) Simplified plaque reduction neutralization assay for dengue viruses by semimicro methods in BHK-21 cells: comparison of the BHK suspension test with standard plaque reduction neutralization. J Clin Microbiol 22:250–254
23. Russell PK, Halstead SB (2016) Challenges to the design of clinical trials for live-attenuated tetravalent dengue vaccines. PLoS Negl Trop Dis 10:e0004854
24. Lazo L, Zulueta A, Hermida L, Blanco A, Sanchez J, Valdes I, Gil L, Lopez C, Romero Y, Guzman MG, Guillen G (2009) Dengue-4 envelope domain III fused twice within the meningococcal P64k protein carrier induces partial protection in mice. Biotechnol Appl Biochem 52:265–271
25. Clements DE, Coller BA, Lieberman MM, Ogata S, Wang G, Harada KE, Putnak JR, Ivy JM, McDonell M, Bignami GS, Peters ID, Leung J, Weeks-Levy C, Nakano ET, Humphreys T (2010) Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. Vaccine 28:2705–2715
26. Govindarajan D, Meschino S, Guan L, Clements DE, Ter Meulen JH, Casimiro DR, Coller BA, Bett AJ (2015) Preclinical development of a dengue tetravalent recombinant subunit vaccine: immunogenicity and protective efficacy in nonhuman primates. Vaccine 33:4105–4116
27. Innis BL, Eckels KH (2003) Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command. Am J Trop Med Hyg 69:1–4
28. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, Endy TP, Raengsakulrach B, Rothman AL, Ennis FA, Nisalak A (2000) Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 181:2–9
29. Gagnon SJ, Ennis FA, Rothman AL (1999) Bystander target cell lysis and cytokine production by dengue virus-specific human CD4(+) cytotoxic T-lymphocyte clones. J Virol 73:3623–3629
30. Weiskopf D, Sette A (2014) T-cell immunity to infection with dengue virus in humans. Front Immunol 5:93
31. Weiskopf D, Cerpas C, Angelo MA, Bangs DJ, Sidney J, Paul S, Peters B, Sanches FP, Silvera CG, Costa PR, Kallas EG, Gresh L, De Silva AD, Balmaseda A, Harris E, Sette A (2015) Human CD8+ T-cell responses against the 4 dengue virus serotypes are associated with distinct patterns of protein targets. J Infect Dis 212:1743–1751
32. Gil L, Cobas K, Lazo L, Marcos E, Hernández L, Suzarte E, Izquierdo A, Valdés I, Blanco A, Puentes P, Romero Y, Pérez Y, Guzmán G, Guillén G, Hermida L (2016) A tetravalent formulation based on recombinant nucleocapsid-like particles from dengue viruses induces a functional immune response in mice and monkeys. J Immunol 197(9):3597–3606
33. Prestwood TR, Morar MM, Zellweger RM, Miller R, May MM, Yauch LE, Lada SM, Shresta S (2012) Gamma interferon (IFN-gamma) receptor restricts systemic dengue virus replication and prevents paralysis in IFN-alpha/beta receptor-deficient mice. J Virol 86:12561–12570
34. Gunther VJ, Putnak R, Eckels KH, Mammen MP, Scherer JM, Lyons A, Sztein MB, Sun W (2011) A human challenge model for dengue infection reveals a possible protective role for sustained interferon gamma levels during the acute phase of illness. Vaccine 29:3895–3904
35. Jeewandara C, Adikari TN, Gomes L, Fernando S, Fernando RH, Perera MK, Ariyaratne D, Kamaladasa A, Salimi M, Prathapan S, Ogg GS, Malavige GN (2015) Functionality of dengue virus specific memory T cell responses in individuals who were hospitalized or who had mild or subclinical dengue infection. PLoS Negl Trop Dis 9:e0003673
36. Yauch LE, Shresta S (2008) Mouse models of dengue virus infection and disease. Antiviral Res 80:87–93
37. Rees W, Bender J, Teague TK, Kedl RM, Crawford F, Marrack P, Kappler J (1999) An inverse relationship between T cell receptor affinity and antigen dose during CD4(+) T cell responses in vivo and in vitro. Proc Natl Acad Sci USA 96:9781–9786
38. Mazzanti B, Hemmer B, Traggiai E, Ballerini C, McFarland HF, Massacesi L, Martin R, Vergelli M (2000) Decrypting the spectrum of antigen-specific T-cell responses: the avidity repertoire of MBP-specific T-cells. J Neurosci Res 59:86–93
39. Alexander-Miller MA, Leggatt GR, Berzofsky JA (1996) Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci USA 93:4102–4107
40. + T cells in xenografted nude mice. J Immunol 170:1183–1190
41. Byers DE, Lindahl KF (1999) Peptide affinity and concentration affect the sensitivity of M3-restricted CTLs induced in vitro. J Immunol 163:3022–3028
42. Alexander-Miller MA, Leggatt GR, Sarin A, Berzofsky JA (1996) Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. J Exp Med 184:485–492
43. Hermida L, Bernardo L, Martin J, Alvarez M, Prado I, Lopez C, Sierra BL, Martinez R, Rodriguez R, Zulueta A, Perez AB, Lazo L, Rosario D, Guillen G, Guzman MG (2006) A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine 24:3165–3171
44. Gil L, Marcos E, Izquierdo A, Lazo L, Valdes I, Ambala P, Ochola L, Hitler R, Suzarte E, Alvarez M, Kimiti P, Ndung’u J, Kariuki T, Guzman MG, Guillen G, Hermida L (2015) The protein DIIIC-2, aggregated with a specific oligodeoxynucleotide and adjuvanted in alum, protects mice and monkeys against DENV-2. Immunol Cell Biol 93:57–66